Kestra Medical Reports Q4 and Fiscal Year 2026 Financial Results
Kestra Medical (NASDAQ: KMTS) reported strong revenue growth in the fourth quarter of fiscal year 2026, with $28.6 million in revenue representing a 66% increase driven by market share gains and expansion in its wearable cardioverter defibrillator category. The company also raised full-year guidance for fiscal 2027 to $137 million, projecting continued growth.
Tickers: $KMTS
Topics: gross_margin_expansion guidance prescription_volume revenue_growth